drugset / Trial / NCT06737250
NB02 (Poseltinib) Combined Rituximab and Lenalidomide in R/R PCNSL
NaSingle-groupOpen-labelTreatment
Summary
An Open, Single treatment arm, Multi-center, Prospective, Phase 2 Trial to Evaluate Efficacy and Safety of NB02 (Poseltinib) combined with Rituximab and Lenalidomide as a Salvage Therapy for Patients with Relapsed or Refractory Primary Central Nervous System Lymphoma
Timeline
- Start
- 2024-11-25
- Primary completion
- 2026-06-30
- Completion
- 2027-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lenalidomide | Other / unclassified | 20 mg | Oral |
| Subject | Poseltinib | Unknown | 60 mg | Oral |
| Subject | Rituximab | Monoclonal antibody | 375 mg/m2 | Intravenous |